Improve + Protect
Developing innovative therapeutics to improve treatment outcomes and protect against the progression of age-related and chronic diseases.
About
Vandria is a clinical stage biotech company developing first-in-class small molecules against a novel target to restore mitochondrial function and reduce inflammation for the treatment of age-related and chronic diseases.
About
Vandria is a clinical stage biotech company developing first-in-class small molecules against a novel target to restore mitochondrial function and reduce inflammation for the treatment of age-related and chronic diseases.
Clinical Pipeline
The company’s lead clinical CNS asset, VNA-318, has successfully completed First-in-Human Phase 1 clinical trial demonstrating safety and tolerability, as well as a PK profile suitable for oral once-daily dosing in humans.
VNA-318 is an orally available, first-in-class, brain-penetrant, patent-protected small molecule with a dual mode of action to improve short term memory and learning, and to have long term disease-modifying effects.
Vandria has a wider portfolio of small molecules against its novel target across a broad range of age-related and chronic diseases of the muscle, lung and liver.
“We believe that VNA-318 has the potential to address unmet medical needs related to cognitive impairment associated with Alzheimer’s disease, major depressive disorder, and other diseases of the CNS.”
Klaus Dugi, MD, CEO of Vandria
Investors
The company has raised $32M Seed and Series A funding in venture finance from ND Capital, Hevolution Foundation, Dolby Family Ventures and private investors and has received over $4M non-dilutive grant funding from InnoSuisse and Eurostars.
Location
Founded in September 2021, Vandria is based at the Biopôle campus in Lausanne Switzerland.
